



SafER Medical Products are Improving Global Respiratory Health in Third World Settings

“Poverty is the mother of inequality in health.”

The unequal distribution of healthcare availability and resources in lower income countries is a huge contributor to negative health outcomes.

In low-income countries, the life expectancy is 34 years lower and the under 5-year mortality rate 100 times higher than in developed countries. Many of these deaths can be attributed to airborne respiratory infections spreading among vulnerable populations or unprotected healthcare workers.



The World Health Organization cites a staggering half of the world’s population lacks access to healthcare due to extreme poverty, financial distress prevents their ability to pay for services.

Critical issues facing developing countries include the impact of long covid, air pollution resulting from wildfires caused by climate change, and lower respiratory infections like tuberculosis, RSV, and influenza.

As the world continues to recover from the economic and financial impact of the COVID 19 pandemic, leaders in healthcare across the globe recognize the need to ensure that level of catastrophic impact does not occur again.

SafER Medical believes we can do better.

Created by a team of front-line medical providers with decades of experience, SafER Medical’s innovative portable negative pressure system (PNPS), Respiratory Shield and Endoshield offers a 99% effective solution to preventing the spread of airborne respiratory infected particles.



Weighing only six pounds, SafER’s PNPS is portable, lightweight and easy to transport. This means SafER systems are an ideal solution for developing countries where much of the medical service delivery must be provided in remote, hard-to-reach locations.

This “go anywhere” capability means SafER PNPS devices can be easily transported via helicopter, light aircraft, river boat, all-terrain vehicles or even on foot.

The respiratory shield stays with the patient from initial intake and throughout emergency transport, hospital waiting rooms, and their entire hospital stay. The portable protective system prevents emergency medical workers from exposure to infected particles even before patient diagnosis.



SafER Medical Products are Improving Global Respiratory Health in Third World Settings

The current gold standard for treating airborne respiratory illnesses in the United States are negative pressure rooms in hospitals. Generally, a hospital will have one room, requiring specific sanitization and depressurization protocols between patients.

Treatment and sanitization take significant time between patients, leading to long treatment wait times and more exposure of other patients and healthcare workers to the airborne respiratory particles. In high volume situations, such as respiratory disease outbreaks, the slow treatment processes in negative pressure rooms mean protocols are often not completed to the extent required.

Developing countries often lack the resources and funding for negative pressure hospital rooms that can cost over \$100,000, leaving simple face masks as their only line of defense, EMS workers are exposed to infections that could otherwise be avoided with an effective PNPS like SafER Medical's.



With limited access to advanced medical facilities, respiratory illnesses such as pneumonia, tuberculosis, flu, chronic obstructive pulmonary disease (COPD), and COVID are treated through a combination of community health strategies, basic medical care, and public health initiatives.

TB kills over a million people each year, and the SafER Portable Isolation Systems can be utilized to help mitigate the spread.

Third World countries often lack the resources we are used to in the Western World, and the SafER Isolation System can help mitigate this divide.

SafER portable respiratory isolation systems are being called the "latex gloves" of respiratory care.



This is because they perform a critical, front-line, prevention function - protecting patients and health care workers - even before the specific type of illness can be diagnosed.

SafER's Chief Operating Officer, Todd Baker, MD, FACEP, calls airborne infected particles a 'total disruptor' to the medical system, because aerosolized illnesses spread like 'wildfire' without effective prevention measures.

Dr. Baker and the SafER team are revolutionizing the medical industry by mitigating the cost, morbidity, and mortality of respiratory illness.

In addition, SafER portable systems can be used to administer aerosolized medications to patients with 42% higher efficacy while eliminating risks from fugitive particles.

As SafER's capabilities have been proven out in Western medical settings, the technology is also now catching the attention of international organizations like Médecins Sans Frontières (Doctors Without Borders), the WHO, and the Red Cross that provide crucial medical support and resources to treat respiratory illnesses and other diseases in under-served areas.

For more information on SafER capabilities or to discuss global deployment opportunities, contact Carl Baker, SafER CEO, at cbaker@safERmedicalproducts.com